The Alzheimer's Study Group was established on July 11, 2007 under the auspices of the Congressional Task Force on Alzheimer’s Disease with the charge of creating a National Alzheimer's Strategic Plan to overcome America’s mounting Alzheimer's crisis.
The National Alzheimer's Strategic Plan was released at a hearing before the U.S. Senate Special Committee on Aging on Wednesday, March 25th at 10:30 a.m. EDT.
The Alzheimer’s Study Group Strategic Plan>
Cure Alzheimer’s Fund recognizes the significant work of the Alzheimer’s Study Group and appreciates the solid framework they developed for a strategic national plan. However, we also believe we must be more aggressive and ambitious in defining a research agenda and timelines for development of effective therapies in our battle against this devastating disease. The last two decades have shown that understanding the causes and genetic risk factors for Alzheimer’s is absolutely critical to determining the disease models on which effective treatments and a potential cure should be based.
Cure Alzheimer’s Fund’s Statement on the Alzheimer’s Study Group’s Strategic Plan>
The Alzheimer's Study Group Strategic Plan provides a solid framework for a strategic national plan to combat the growing crisis of Alzheimer’s disease. It is clear that all involved in this report worked hard to develop a comprehensive strategy for the treatment and care of the more than 5.2 million Americans already battling Alzheimer’s and the 10 million caregivers across the country grappling with the challenges of caring for a loved one with the disease.
The Alzheimer's Study Group Strategic Plan>
Cure Alzheimer's Fund proposes a National Research Strategy to accelerate progress toward a cure. The proposal builds on our own Research Roadmap, and provides a broader path to intervention by 2020.
We have shared this draft with selected members of Congress and their staffs, and with the staff of the Alzheimer's Study Group , a bipartisan effort co-chaired by Newt Gingrich and former Senator Bob Kerrey, and featuring others including Justice Sandra Day O’Connor, Harold Varmus and our own Henry McCance. It is our goal to work collectively with other funding organizations, the National Institutes of Health and related government agencies to avert the looming crisis of Alzheimer’s. If we can agree on the fundamentals of a national research strategy, we can save millions of lives and billions of dollars within the next decade.
Cure Alzheimer's Fund's National Research Strategy>
Q&A on National Research Strategy>
Dr. Sisodia of the University of Chicago and Dr. Gabe of the University of California at Irvine have been awarded the prestigious distinction of fellow of the American Association for the Advancement of Science (AAAS). Founded in 1848, AAAS is the world’s largest general scientific society and publisher of the journal Science.
Dr. Sisodia, a member of the Cure Alzheimer's Fund Research Consortium, is being recognized “for extraordinary contributions to understanding the function and dysfunction of APP and Presenilin 1 in cellular and animal models of Abeta amyloidosis in Alzheimer’s disease.”
Read more in the University of Chicago Chronicle
Dr. Glabe is also a member of the Cure Alzheimer’ Fund Research Consortium and a Professor of Molecular Biology & Biochemistry School of Biological Sciences at UC Irvine. He was one of 20 UC Irvine science and engineering researchers named as AAAS fellows, the largest class in 2008 of any university or institution in the United States.
Alzheimer's Charity Finds Success in Stuart, FL. A recent TC Palm article features the breakthrough work of the Alzheimer's Genome Project and describes the origin of Cure Alzheimer's Fund.
By BY JAN LINDSEY Correspondent
Wednesday, December 24, 2008
STUART — Philanthropist Phyllis Rappaport, a Stuart resident, knows how to pick 'em. The Rappaports were one of four families to found the Cure Alzheimer's Fund in 2004, primarily to back the work of Rudy Tanzi, a scientist affiliated with Harvard University and Massachusetts General Hospital. This year, Tanzi identified 40 human genes related to Alzheimer's and made Time magazine's list of the Top 10 Medical Breakthroughs of 2008.
Boston Globe story focuses on Cure Alzheimer's Fund study that shows mice given an anesthetic widely used in surgery on people suffered changes to their brains similar to the damage found in Alzheimer's disease. The results by researchers from Dr. Rudy Tanzi of Massachusetts General Hospital was published in the online Annals of Neurology. The results need to be tested in humans, the authors caution, but the findings raise questions about administering this kind of anesthesia to elderly patients with or without Alzheimer's.
Click here to read the full article
The first family-based genome-wide association study in Alzheimer’s disease has identified the sites of four novel genes that may significantly influence risk for the most common late-onset form of the devastating neurological disorder.
Four novel genes that may significantly increase the risk of the most common form of late-onset Alzheimer’s have been identified by researchers at Massachusetts General Hospital and Harvard Medical School, as reported in the November 7th issue of American Journal of Human Genetics. The findings, part of a larger “Alzheimer’s Genome Project” (AGP) established three years ago to identify the full set of Alzheimer’s disease genetic risk factors, may lead to more aggressive therapeutic interventions to slow, stop or even reverse the effects of the disease. These new therapies would differ from current treatments that only address the symptoms of the disease.
The award co-sponsored by the Cure Alzheimer's Fund and the Alzheimer's Association honors the legacies of two pioneering Alzheimer researchers, George G. Glenner and Leon J. Thal. The two $100,000 grants will be made to early career researchers to inspire and enable innovative research which leads to effective therapies for Alzheimer's Disease.
© 2005-2015 Cure Alzheimer's Fund. All rights reserved.